Ficlatuzumab, a mAB that targets the HGF/c-MET axis, is also being tested in clinical trials for HNSCC in combination with Cetuximab in R/M-HNSCC (NCT02277197). The gene discussed is MET; the disease is head and neck squamous cell carcinoma.